An outstanding management team composed of high-level talents with overseas pharmaceutical R&D background and extensive commercialization experience.
-
Management Team -
Honors CourseUtidelone has been selected twice for oral presentations at the ASCO annual meeting and approved in 2021 for the treatment of mBC.
-
PartneringWe are actively selecting partners. Please contact our BD team via bd@biostar-pharma.com.
-
Who we areAs an innovative cancer drug company driven by synthetic biology technology, Beijing Biostar successfully listed in Hong Kong.
News
-
2024-11-14Company News
Biostar to collaborate with Baheal Medical to accelerate the commercialization process of Utidelone -
2024-10-31Company NewsBeijing Biostar successfully landed on the main board of the Hong Kong Stock Exchange, synthetic biology leads the new era of innovative drug research and development
-
2024-09-30Company NewsPreliminary data released from a clinical study of Utidelone for the first-line treatment of advanced pancreatic cancer
-
2024-09-03Company NewsBiostar Announces Completion of Patient Recruitment for US Phase 1 Clinical Study of Utidelone Capsule
-
2024-07-05Company NewsBiostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis
-
2024-03-28Company News73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis
-
2024-03-21Company News100% CBR! FDA Granted ODD to Biostar Pharma's Utidelone Capsule (UTD2) for the Treatment of Gastric Cancer
-
2023-06-16Company NewsFDA Approved Utidelone Injectable (UTD1) Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer
-
2023-06-12Company NewsBiostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)—The World's First Oral Epothilone Anti-Cancer Drug
